A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
Authors:
- Mustafa Ender Terzi̇oĞluMTMustafa Ender Terzi̇oĞlu
- Yusuf KarabulutYKYusuf Karabulut
- Zevcet YilmazZYZevcet Yilmaz
- Emi̇nE Fi̇gEn TarhanETEmi̇nE Fi̇gEn Tarhan
- Mehmet Emi̇n Eneci̇kMEMehmet Emi̇n Eneci̇k
- Adem KüçükAKAdem Küçük
- Ayşe AyanAAAyşe Ayan
- Meti̇n ÖzgenMÖMeti̇n Özgen
- Uğur KarasuUKUğur Karasu
- Servet YolbaşSYServet Yolbaş
Open Access
- 1 January 2023
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (3) , 731-743
Abstract
Background/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting. Materials and methods: Data gathered from patients' files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined. Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres- sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve- ment at Month 6 [OR = 0.31, 95% CI (0.14- 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13-0.94), p = 0.037]. Overall, 25 mild adverse events were reported. Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.Keywords
This publication has 31 references indexed in Scilit:
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practiceAnnals of the Rheumatic Diseases, 2012
- TNF inhibitor therapy for rheumatoid arthritisBiomedical Reports, 2012
- ACR/EULAR 2010 rheumatoid arthritis classification criteriaRheumatology, 2012
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE studyAnnals of the Rheumatic Diseases, 2012
- Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registryAnnals of the Rheumatic Diseases, 2011
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals of the Rheumatic Diseases, 2010
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care‐based incident case‐control study in Norfolk, EnglandArthritis & Rheumatism, 1997